Sarah Lynne Hellman

Title: Innovations of Sarah Lynne Hellman

Introduction

Sarah Lynne Hellman is a prominent inventor based in Indianapolis, IN (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific receptors in the brain. With a total of three patents to her name, her work has the potential to impact the treatment of various medical conditions.

Latest Patents

One of her latest patents is titled "2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines as 5-HT7 receptor antagonists." This invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine, persistent pain, and anxiety. The compounds are designed to selectively target the 5-HT7 receptor, which plays a crucial role in these medical conditions.

Career Highlights

Sarah is currently employed at Eli Lilly and Company, a leading pharmaceutical company known for its innovative research and development. Her work at Eli Lilly has allowed her to focus on creating effective treatments that can improve the quality of life for patients suffering from various ailments.

Collaborations

Throughout her career, Sarah has collaborated with notable colleagues, including Michael Philip Cohen and Michael Wade Tidwell. These collaborations have fostered a productive environment for innovation and have contributed to the advancement of her research.

Conclusion

In summary, Sarah Lynne Hellman is an accomplished inventor whose work in the pharmaceutical industry has led to significant advancements in the treatment of migraine, pain, and anxiety. Her contributions continue to shape the future of medical research and innovation.